AC Immune (ACIU) Projected to Announce Earnings on Tuesday

AC Immune (NASDAQ:ACIU) is projected to issue its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect AC Immune to announce earnings of ($0.22) per share and revenue of $0.33 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 12:30 PM ET.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The firm had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. On average, analysts expect AC Immune to post ($0.60) EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

AC Immune Price Performance

NASDAQ ACIU opened at $2.31 on Tuesday. The firm’s 50-day moving average is $2.64 and its two-hundred day moving average is $2.76. AC Immune has a 12 month low of $2.10 and a 12 month high of $4.00. The stock has a market capitalization of $235.10 million, a P/E ratio of -4.28 and a beta of 1.56.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ACIU. Weiss Ratings cut shares of AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 20th. Zacks Research upgraded shares of AC Immune from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 29th. BTIG Research reiterated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a report on Wednesday, September 23rd. Finally, HC Wainwright restated a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.